Chairman of the Board
Ulf Rosén is co-founder and chairman of Intrance Medical Systems, Inc. and Intrance Holdings AB.
Mr. Rosén has over 35 years of proven experience in the pharmaceutical and medical technology industry including more than 20 years at start-up and early-stage companies as investor, CEO and member of the board/chairman. During his career, he has been directly involved in several strategic investments and M&A activities and has extensive experience in Parkinson’s disease. Mr. Rosen was instrumental in pioneering the development of levodopa-carbidopa intestinal gel commercialized in the EU member states as Duodopa®. Such success led to its acquisition by Solvay Phamaceuticals and Abbott/AbbVie where Duopa® was subsequently approved in the United States.
Mr. Rosén was co-founder and CEO of Lobsor Pharmaceuticals which was acquired by STADA/Britannia in September 2020. Previously, he held senior management positions in larger organizations as CEO for Pharmacia & Upjohn Norway as well as executive vice president of Fresenius Kabi Global Nutrition Division. He currently serves as an independent board member of Acarix AB (listed at Nasdaq FN).
He holds a BSc from Mälardalen University (Sweden), and master’s degrees in business administration and general management from IHM Business School and executive financial management from INSEAD.
*The product, Duopa® in U.S./Duodopa® in Europe, mentioned above is a registered trademark of AbbVie.
Chief Executive Officer and Board Member
Patrick Shea is the chief executive officer at Intrance Medical Systems, Inc. In this role, he is responsible for building the company’s infrastructure to develop and commercialize its novel treatment for advanced Parkinson’s disease. He is also a member of the board. Mr. Shea has proven experience in leading and growing commercial organizations within the pharmaceutical and biotechnology industry across a diverse set of companies, markets and therapeutic areas. Additionally, he has successfully led a number of specialty product launches and has significant strategic business development expertise.
In his most recent position, Mr. Shea served as senior vice president of commercial at Antares Pharmaceuticals. Prior, he served in chief commercial officer roles at Eaglet Corporation and Clarus Therapeutics. Mr. Shea has also held executive leadership positions at CSL Behring, Astellas Pharmaceuticals U.S. and commercial assignments of increasing responsibility at Ligand Pharmaceutical and Boehringer Ingelheim Pharmaceuticals.
He holds a bachelor of arts degree from Alfred University.
Fredrik Buch, M.D., Ph.D.
Fredrik Buch, M.D., Ph.D., joined Intrance Medical Systems, Inc. as director of the board in 2018. He has significant experience in both clinical work and drug development in the pharmaceutical sector as well as profound experience in company start-ups, fund investing and financing.
He is a director of a number of life science companies in Sweden, including Lantmännen Medical AB, Cytovac AB and Acarix AB and serves as chairman at Huvudsta Vårdcentral AB, Tridentify AB and Citadellet AB.
In addition, Dr. Buch has served as head of SEB Healthcare Funds and partner at HealthCap and has been acting as a financial advisor to start-up companies, raising capital and serving on various boards in Sweden and abroad since 2000. He has served on more than 20 boards prior to joining Intrance. During his career, he has held several clinical research positions at leading pharmaceutical and biotechnology companies, including Bristol Myers Squibb, Hoechst, Pharmacia and Pharmacia & Upjohn, and has authored more than 20 scientific publications.
Dr. Buch is an orthopedic surgeon and scientist by training and holds an M.D. in medicine and a Ph.D. from the University of Gothenburg.
Ed Schutter, R.Ph., M.B.A.
Ed Schutter joined Intrance Medical Systems, Inc. as director of the board in January 2022, becoming the company’s first U.S.-based board member. He has over forty years of pharmaceutical industry experience and most recently served as chief executive officer of Arbor Pharmaceuticals.
Prior to Arbor, Mr. Schutter served as president of Sciele (Shionogi) Pharmaceuticals. Previously, he served as vice president of global business development at Solvay Pharmaceuticals based in Basel, Switzerland. He also held several senior management roles at the U.S. subsidiary of Solvay during his twenty years with the organization. Mr. Schutter began his pharmaceutical career with Reid-Provident Labs, a small entrepreneurial pharmaceutical company based in Atlanta, GA.
He currently serves on the boards of directors of several public and private companies and has been a previous board member for several non-profit organizations, including Mercer University Board of Trustees, the American Diabetes Association and American Heart Association.
Mr. Schutter is a registered pharmacist and holds a BSc in pharmaceutical sciences from Mercer University and a master’s degree in business administration from Kennesaw State University. In addition, he completed graduate studies in international business at Njienrode University, Amsterdam, Netherlands.